Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-10-01
|
| Series: | Liver Cancer |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/512170 |
| _version_ | 1818301355147657216 |
|---|---|
| author | Masatoshi Kudo |
| author_facet | Masatoshi Kudo |
| author_sort | Masatoshi Kudo |
| collection | DOAJ |
| first_indexed | 2024-12-13T05:21:41Z |
| format | Article |
| id | doaj.art-2e3b4a07c0164e4cab0c08d42ef1fc36 |
| institution | Directory Open Access Journal |
| issn | 2235-1795 1664-5553 |
| language | English |
| last_indexed | 2024-12-13T05:21:41Z |
| publishDate | 2020-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Liver Cancer |
| spelling | doaj.art-2e3b4a07c0164e4cab0c08d42ef1fc362022-12-21T23:58:18ZengKarger PublishersLiver Cancer2235-17951664-55532020-10-019662963910.1159/000512170512170Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular CarcinomaMasatoshi Kudohttps://www.karger.com/Article/FullText/512170immune checkpoint inhibitorsatezolizumabbevacizumabcombination immunotherapy |
| spellingShingle | Masatoshi Kudo Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma Liver Cancer immune checkpoint inhibitors atezolizumab bevacizumab combination immunotherapy |
| title | Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma |
| title_full | Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma |
| title_fullStr | Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma |
| title_full_unstemmed | Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma |
| title_short | Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma |
| title_sort | limited impact of anti pd 1 pd l1 monotherapy for hepatocellular carcinoma |
| topic | immune checkpoint inhibitors atezolizumab bevacizumab combination immunotherapy |
| url | https://www.karger.com/Article/FullText/512170 |
| work_keys_str_mv | AT masatoshikudo limitedimpactofantipd1pdl1monotherapyforhepatocellularcarcinoma |